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154Medical comorbidities but not interventions
adversely affect survival in patients with intermittent
claudication
Marcus R. Kret, MD,a Kenneth H. Perrone, BA,b Amir F. Azarbal, MD,a Erica L. Mitchell, MD,a
Timothy K. Liem, MD,a Gregory J. Landry, MD,a and Gregory L. Moneta, MD,a Portland, Ore; and
Brooklyn, NY
Objective: Intermittent claudication (IC) is common and associated with decreased survival. While patients with IC
infrequently progress to critical limb ischemia (CLI), many elect to pursue intervention initially or during follow-up.
However, controversy exists as to whether intervention in patients with IC adversely impacts survival or limb salvage.
The purpose of this study was to characterize patient demographics and comorbidities with respect to differences in
survival and limb salvage among patients who elect no intervention (NI) vs those electing immediate intervention (II) or
delayed intervention (DI) for IC.
Methods: Patients referred to a university practice for limb ischemia were identiﬁed via a query of the electronic medical
record from 2007 to 2011. Patients with prior lower extremity interventions or CLI were excluded. IC patients were
classiﬁed according to intervention: NI during follow-up, II, and DI. Patient demographics, Charlson morbidity index,
survival, and reintervention rates were analyzed.
Results: A total of 262 of 1320 patients met inclusion criteria. Thirty patients with possible IC were believed to have
nonarterial related symptoms. Study patients included 132 with NI, 62 with II, and 38 with DI. DI patients were
younger and less frequently diabetic (median age, 65.5 years, 63.5 years, 58.0 years; P [ .002; diabetes, 43.2%, 39.5%,
22.6%; P [ .02 for NI, II, and DI, respectively). NI patients had higher Charlson comorbidity scores (P < .05).
Hypertension, hyperlipidemia, and diabetes were associated with decreased survival in all groups (P < .05). Median
survival was greatest for DI patients and least for NI patients (NI 92 months, II 95 months, DI 143 months; log-rank[
.015). Primary patency of interventions at 1 and 5 years were equal for II and DI patients (1 year, II 80% vs DI 79%;
5 years, II 45% vs DI 50%; P [ .9). Reintervention was common with rates similar between the II and DI groups
(P > .05). Four of 38 DI patients required minor amputation for progression to CLI. There were no major am-
putations in any group.
Conclusions: Progression to CLI is uncommon in IC. Survival of claudicants is decreased by diabetes, hypertension, and
hyperlipidemia but not by intervention for IC. Reintervention is common in treated IC patients but no different among
those undergoing II and DI. Intervention did not lead to major amputation. II or DI in IC patients does not affect
survival or major amputation. (J Vasc Surg 2013;58:1540-6.)Peripheral arterial disease (PAD) has an overall prev-
alence between 3% and 10%, including as many as 20% of
patients over 70 years old.1,2 Intermittent claudication
(IC) is a common manifestation of PAD. In addition
to limb-speciﬁc morbidity, patients with IC are at
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0principally myocardial infarction and stroke.1,3-7 As
a result, initial recommendations for patients with IC
include smoking cessation, atherosclerotic risk factor
modiﬁcation, and treatment with aspirin, statins, and
structured exercise regimens.1,8,9 However, there is
evidence to suggest patients and physicians struggle to
maintain strict adherence to these recommendations,
and thus, these patients may beneﬁt from referral to
vascular surgery specialty clinics.10,11 Though few claudi-
cants progress to critical limb ischemia (CLI),1,12-14
patients may choose endovascular and/or operative
interventions for lifestyle-limiting claudication. How-
ever, the need for ongoing surveillance and the potential
for additional intervention may have a negative impact
on quality of life. In addition, the impact of interventions
on limb salvage and overall survival in patients with IC
remains uncertain. We sought to characterize patient
demographics and comorbidities with respect to differ-
ences in survival and limb salvage among patients who
elect no intervention (NI) vs those electing immediate
intervention (II) or delayed intervention (DI) for IC.
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should be offered an intervention from those who should
be managed with medical therapies alone.
METHODS
Our study was an institutional review board approved
retrospective review of patients referred to the vascular
surgery clinic at Oregon Health and Science University
for initial consultation for IC. Patients were identiﬁed via
a query of the electronic medical record using International
Classiﬁcation of Diseases, Ninth Revision codes (440.2x
“atherosclerosis of native arteries of the extremities,”
443.9 “peripheral vascular disease, unspeciﬁed”) for the
time period ranging from 2007 to 2011. Of the patients
identiﬁed by this search, several had an initial visit prior
to 2007. When dictated consult notes were available
from these initial visits in our current electronic medical
record, these patients were included in the study. As
a result, the dates of initial consultation actually ranged
from January 1999 to June 2011, with follow-up tracked
through June 2012. Patients who had previous lower
extremity arterial interventions or documented evidence
of CLI at the time of their ﬁrst clinical encounter at our
institution were excluded from analysis.
Demographic data included age at ﬁrst patient
encounter and sex. In addition, we recorded comorbidities
for each patient as documented in the initial consult note.
These included coronary artery disease (deﬁned as presence
of angina, previous myocardial infarction, percutaneous
coronary intervention, or coronary artery bypass graft),
congestive heart failure, hypertension (deﬁned by systolic
blood pressure >140, diastolic blood pressure >90, or
normal blood pressure with antihypertensive medication
use), hyperlipidemia (deﬁned by elevated high-density lipo-
protein, low-density lipoprotein, or statin use), chronic
obstructive pulmonary disease, and chronic renal disease
(creatinine >1.5). Diagnoses of congestive heart failure
and chronic obstructive pulmonary disease were based on
documentation in the electronic medical record. In addi-
tion, a Charlson comorbidity score was calculated for
each patient using previously published methodology.15
When documented, we noted speciﬁc claudication sym-
ptom characteristics including distance to symptom onset,
time to symptom resolution and duration of symptoms
prior to vascular surgery consultation. We deﬁned “short-
distance claudication” as symptom onset within one city
block, 100 yards, or 3 minutes of walking. Symptom onset
at greater distances/time intervals was considered “long-
distance claudication.” Results of diagnostic studies were
recorded and included bedside and/or vascular laboratory
ankle-brachial index (ABI) measurement, arterial duplex,
computed tomography angiography, magnetic resonance
angiography, and/or conventional angiography.
Our typical ﬁrst encounter with patients evaluated for
symptoms of claudication includes discussion of several
factors. First, we discuss the associated risks of cardiovas-
cular morbidity and mortality, and discuss the importanceof risk factor modiﬁcation including smoking cessation as
well as aspirin and statin therapy. In addition, we explain
the beneﬁts of regular exercise in increasing walking
distance. Finally, we describe the low risk of progression
to CLI and limb loss. With this in mind, the decision to
proceed with additional diagnostic work-up and ultimately
intervention is an individualized one made jointly by the
attending vascular surgeon and the patient. We generally
do not offer intervention unless symptoms cause signiﬁcant
impairment in either the patients’ ability to work or to
pursue their desired leisure activities. In addition, patient
comorbidities are carefully considered before any interven-
tion is offered. Patients who choose a trial of medical
management are followed at 3- to 6-month intervals
initially and 6 to 12 months thereafter. These patients are
offered intervention if they believe that medical therapy
has not provided adequate symptom relief, or if they expe-
rience symptom progression during the period of medical
management.
Patients were stratiﬁed according to whether or not
they ultimately underwent intervention, and further strati-
ﬁed by the timing of intervention. For the purposes of our
study, any therapeutic endovascular procedure (angioplasty
and/or stenting) or traditional open vascular operation was
considered an intervention, whereas diagnostic procedures
were not. Patients were classiﬁed as “immediate interven-
tion” (II) if intervention was recommended at their initial
clinic visit. Patients who underwent intervention following
a period of observation with attempted medical optimiza-
tion in lieu of intervention were categorized as “delayed
intervention” (DI), whereas those who did not undergo
any intervention during the follow-up period were catego-
rized as “no intervention” (NI). In patients who under-
went intervention, need for reintervention or amputation
during the postoperative period was noted. Mortality was
recorded as documented in the electronic medical record,
and cross-referenced with the Social Security Death Index.
Statistical analyses were performed with IBM SPSS
Statistics v 20 (IBM Corporation, Armonk, NY). Descrip-
tive statistics were used to characterize the various demo-
graphics and comorbidities. Comparisons across the three
intervention groups were performed using analysis of vari-
ance (ANOVA). Post-hoc analysis using Tukey honestly
signiﬁcant difference (HSD) was employed to identify
signiﬁcant differences between individual groups. Primary
patency and all-cause mortality were calculated using the
Kaplan-Meier technique with differences between groups
compared using the log-rank test. Individual Kaplan-
Meier survival calculations were performed for each of
the comorbidities recorded. Multivariate analysis using
Cox regression analysis was performed to assess the impact
of these factors on overall survival. P values of <.05 were
considered statistically signiﬁcant.
RESULTS
Initial query of the medical record based on Interna-
tional Classiﬁcation of Diseases, Ninth Revision codes
Fig 1. Patient groups.
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lower extremity arterial interventions or documented evidence
of CLI, 262 patients met criteria for study inclusion. After
initial evaluation, 30 were judged to have pain attributable
to nonvascular causes. Of the remaining 232 patients, 100
had an intervention to treat symptoms of IC, whereas 132
had no surgical intervention (Fig 1). The median patient
age was 64.0 years. The incidence of various medical
comorbidities is listed in Table I. Though it did not reach
statistical signiﬁcance, a greater proportion of patients in
the DI group had comorbid lower back pain. At the time
of initial consultation, only 65.9% (n ¼ 153) of patients
were taking aspirin, 59.5% (n ¼ 138) were taking a statin,
and 44.4% were taking both drugs concurrently. These
rates were similar across the three intervention groups.
The majority of patients were men (n ¼ 171; 65.3%).
Overall, 53.2% (n ¼ 134) had short distance claudication.
The mean duration of symptoms prior to initial consult
was 40.9 months and was similar across the three interven-
tion groups (NI, 40.4 months; II, 40.1 months; DI,
40.1 months; P ¼ .98). Median follow-up for all patients
was 15.3 months (range, 0-159 months); however, this
differed between intervention groups. Follow-up in the
NI group was the shortest at 6.4 months (range, 0 days-
10.8 years), with median follow-up of 17 months (range,
1 day-9 years) and 64.3 months (range, 3 months-13
years) in the II and DI groups, respectively. Median
follow-up after initial intervention was also longer in the
DI group compared with the II group (DI, 30.7 months;
range, 1 day-9.9 years; II, 15.6 months; range, 1 day-9
years). The mean ABI was 0.67.
Of the 132 patients who had NI, 104 were treated with
medical management alone. In the remaining 28, 10 were
offered an intervention but declined. Among this subset,
four preferred continued exercise therapy, two others
believed their symptoms were manageable and were satis-
ﬁed with their current quality of life, whereas three
declined surgery for unspeciﬁed reasons. The ﬁnal patient
suffered a stroke at the time of a previous cardiac catheter-
ization and was reticent to pursue additional interventions.
Four additional patients were deemed medically unﬁt for
intervention because of multiple medical comorbidities.
Six patients did not return for follow-up, six did not
undergo intervention for unspeciﬁed reasons, and two
others required treatment of a separate disease process
that prohibited intervention for IC.
In the 100 who did have an intervention, 62 under-
went II and 38 underwent DI. The median interval
between initial evaluation and intervention was 26.5 days
for the II group (range, 1 day-11.7 months) and 15.2
months for the DI group (range, 1 month-9.5 years).
There were 54 open and 46 endovascular interventions
performed. These proportions were similar between the
II and DI groups, with 22 (57.9%) open and 16 (42.1%)
endovascular procedures in the II group vs 32 open
(48.4%) and 30 (51.6%) endovascular procedures in the
DI group (c2, P ¼ .54). Endovascular interventions
included iliac artery stenting (n ¼ 40) and superﬁcialfemoral artery angioplasty and/or stenting (n ¼ 6). Open
operations included aortobifemoral bypass (n ¼ 14), iliac
(n ¼ 6), and/or superﬁcial femoral artery (n ¼ 6) endarter-
ectomy, infrainguinal bypass (n ¼ 23), and extra-anatomic
bypasses (n ¼ 5; axillo-femoral and/or femoral-femoral).
As patients were stratiﬁed according to the various proce-
dures performed, there were limited numbers in each
speciﬁc group, and thus, c2 analysis was not performed.
However, the distribution of procedures was generally
similar between the DI and II groups (Table II).
Of the 38 patients in the DI group, 23 were initially
treated medically for their claudication, whereas two
initially declined intervention, and three others DI for
unspeciﬁed reasons. Comorbidities played a role in the
timing of intervention, as seven patients required treatment
of a separate medical condition prior to intervention,
whereas three were initially believed to have symptoms
attributable to nonvascular causes. When clearly listed in
the medical record, the most common indications for inter-
vention were lifestyle limiting claudication (n ¼ 27) and
either symptom progression (n ¼ 23) or failure of improve-
ment (n ¼ 11) in patients who had an initial period of
medical management. Ten of the patients with symptom
progression had documented progression to CLI. Six of
these patients had an intervention to treat rest pain, while
four had progression to tissue loss that ultimately required
minor amputation. The shortest duration between initial
intervention and minor amputation was 128 days. This
was nearly 2 years after initial vascular surgery consultation
in a patient with end-stage renal failure requiring dialysis.
The second patient in our series required minor am-
putation 4.2 years after initial intervention and 5.3 years
after initial consultation in a gentleman who refused
any attempts at smoking cessation despite repeated
Table I. Patient comorbidities
Comorbidity
Total (n ¼ 232),
No. (%)
NI (n ¼ 132),
No. (%)
II (n ¼ 62),
No. (%)
DI (n ¼ 38),
No. (%) P value
Mean age, years 64.0 65.5 63.5 58 .002a
CAD 88 (37.9) 50 (37.9) 18 (47.4) 20 (32.3) .319
Previous MI 32 (13.8) 18 (13.6) 6 (15.8) 8 (12.9) .918
Hypertension 171 (73.7) 102 (77.3) 27 (71.1) 42 (67.7) .343
Cerebrovascular disease 43 (18.5) 27 (20.5) 7 (18.4) 9 (14.5) .611
DM 86 (37.1) 57 (43.2) 15 (39.5) 14 (22.6) .02a
HLD 131 (56.5) 78 (59.1) 21 (55.3) 32 (51.6) .611
COPD 17 (7.3) 11 (8.3) 3 (7.9) 3 (4.8) .677
Smoking .788
Never 28 (12.1) 15 (11.4) 4 (10.5) 9 (14.5)
Former 126 (54.3) 76 (57.6) 20 (52.6) 30 (48.4)
Current 78 (33.6) 41 (31.1) 14 (36.8) 23 (37.1)
Quit smoking after initial consult 18 (23.7) 12 (29.3) 4 (19.0) 2 (14.3) .615
CKD 24 (10.3) 15 (11.4) 2 (5.3) 7 (11.3) .531
Osteoarthritis 22 (9.5) 14 (10.6) 3 (7.9) 5 (8.1) .798
Low back pain 24 (10.3) 11 (8.3) 2 (5.3) 11 (17.7) .071
Other muscular/skeletal 24 (10.3) 14 (10.6) 5 (13.2) 5 (8.1) .735
Aspirin 153 (65.9) 88 (66.7) 43 (69.4) 22 (57.9) .485
Statin 138 (59.5) 79 (59.8) 35 (56.5) 24 (63.2) .796
ASA and statin 103 (44.4) 58 (43.9) 29 (46.8) 16 (42.1) .890
ANOVA, Analysis of variance; ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; DI, delayed intervention; DM, diabetes mellitus; HLD, hyperlipidemia; II, immediate intervention; MI, myocardial infarction;
NI, no intervention; SD, standard deviation.
All comparisons are by c2 analysis with the exception of age, which was compared with ANOVA.
aDenotes signiﬁcant differences.
Table II. Distribution of procedure type by intervention
group
Procedure performed
II (n ¼ 62),
No. (%)
DI (n ¼ 38),
No. (%)
Iliac artery stent 26 (41.9) 14 (36.8)
Superﬁcial femoral artery
angioplasty/stent
4 (6.5) 2 (5.3)
Aortobifemoral bypass 7 (11.3) 7 (18.4)
Extra-anatomic bypass 4 (6.5) 1 (2.6)
Iliac artery endarterectomy 3 (4.8) 3 (7.9)
Femoral artery endarterectomy 3 (4.8) 3 (7.9)
Infrainguinal bypass 15 (24.2) 8 (21.1)
DI, Delayed intervention; II, immediate intervention.
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offered intervention at his initial ofﬁce visit but declined.
The remaining two patients with late minor amputation
had diabetes mellitus as their primary risk factor for disease
progression. The ﬁrst of these patients had a short interval
of nonoperative management (only 30 days) but did not
require amputation until 6.2 years later. The second
had a 3.4-year interval of nonoperative management.
This minor amputation was 9.6 years after initial interven-
tion and 13 years after she was ﬁrst evaluated for symptoms
of IC.
Between the three intervention groups, signiﬁcant
differences in age and diabetes were observed. The NI and
II patients were both signiﬁcantly older than the DI group
(mean ages: NI, 65.5 years; II, 63.5 years; DI, 58.0 years;ANOVA, P ¼ .002; Tukey HSD: NI vs DI, P ¼ .001; II
vs DI, P ¼ .043). The NI (43.2%; n ¼ 57) and II (39.5%;
n ¼ 15) groups also had a higher rate of diabetes when
compared with the DI group (22.6%; n ¼ 14; P ¼ .02).
In addition, Charlson comorbidity scores were calcu-
lated for each intervention group, with higher scores repre-
senting greater number of comorbidities.15 The NI group
had the highest mean score, whereas the DI group had the
lowest; scores were signiﬁcantly different across the three
groups (ANOVA: NI, 5.15; II, 4.32; DI, 3.55; P < .01).
The NI group had a greater number of comorbidities
than either of the other two groups, whereas comorbidities
were similar between the II and DI groups (Tukey
HSD: NI vs II, P ¼ .035; NI vs DI, P < .001; II vs DI,
P ¼ .194).
Patients who underwent II had evidence of worse PAD
when compared with the other two groups. Seventy-one
percent (n ¼ 44) of patients in the II group had short
distance claudication compared with 53.1% (n ¼ 17) in
the DI group, and 47.4% (n ¼ 55) in the NI group, respec-
tively (c2, P < .05). Mean ABI differed signiﬁcantly across
the three intervention groups as well (NI, ABI ¼ 0.68; II,
ABI ¼ 0.60; DI, ABI ¼ 0.7; ANOVA, P ¼ .018). There
was a signiﬁcantly decreased ABI in the II group when
compared with either of the other two groups (Tukey
HSD: NI vs II, P ¼ .035; II vs DI, P ¼ .035; NI vs DI,
P ¼ .773).
Overall mean survival following initial consult was
1256 12.5 months. Kaplan-Meier analyses were performed
for each of the various comorbidities recorded (Table III).
Diabetes, hyperlipidemia, and hypertension were all
Table III. Kaplan-Meier survival estimates for selected
comorbidities
Comorbidity
Kaplan-Meier estimated mean
survival, months 6 95% CI
P value
(log-rank)
Comorbidity
present
Comorbidity
absent
CAD 109.2 6 16.1 130.9 6 15.9 .381
Previous MI 111 6 16.3 122.2 6 15.2 .413
Cerebrovascular
disease
104 6 16.1 124.1 6 15 .904
HTN - - .001a
DM 112.9 6 23 120.7 6 12 .029a
HLD 113.8 6 17.5 116 6 10.8 .036a
Sex
Male 109.7 6 13.6 .224
Female 133.5 6 20.2
Claudication
distance
Short 115.6 6 20.8 .131
Long 123.8 6 13.4
CAD, Coronary artery disease; CI, conﬁdence interval; DM, diabetes mel-
litus; HLD, hyperlipidemia; HTN, hypertension; MI, myocardial infarction.
aDenotes signiﬁcant differences.
Fig 2. Overall survival from initial consult stratiﬁed by treatment
group.
Intervention
Number at risk
0
months
12
months
24
months
36
months
48
months
60
months
DI 38 34 31 26 25 20
II 62 36 30 26 15 13
NI 132 61 47 33 26 13
DI, Delayed intervention; II, immediate intervention; NI, no intervention.
The number at risk in each group for each time interval is presented.
Standard error did not exceed 0.10 in any group over the 5-year time period
presented.
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during the course of follow-up, all had hypertension. As
a result, Kaplan-Meier estimated mean survival could not
be calculated for this comorbidity as all patients without
hypertension were censored. Survival also differed across
the three intervention groups (Fig 2). Mean survival for
patients in the NI group was 92.1 6 15.5 months,
compared with 94.9 6 10.9 months in the II group and
143.4 6 16.1 months in the DI group (log-rank, P ¼
.015). Multivariate Cox regression analysis was performed
to further delineate factors associated with decreased overall
survival. By this measure, age (hazard ratio, 1.1; 95% conﬁ-
dence interval, 1.04-1.189; P ¼ .001) and diabetes (hazard
ratio, 8.5; 95% conﬁdence interval, 2.3-31.5; P ¼ .001)
were the only comorbidities that remained signiﬁcant risk
factors for mortality.
For patients who had an intervention, the need for rein-
tervention was common. In the II group, 16/38 (42%)
patients required at least one additional intervention
compared with 18/62 (29%) in the DI group; this differ-
ence was not signiﬁcantly different (c2, P ¼ .39). However,
reintervention was more common in patients who under-
went endovascular procedures (37%; n ¼ 17) compared
with those who had an open intervention (31.5%; n ¼
17), a difference that did reach signiﬁcance (c2, P ¼
.028). The mean time to initial reintervention was
27.7 months overall and was also similar between groups
(II, 34.3 months; DI, 23.7 months; t-test, P ¼ .10). In
addition, primary patency was similar between intervention
groups at both 1 year (II, 80% vs DI, 79%) and 5 years (II,
45% vs DI, 50%; log-rank, P ¼ .9 for overall primary
patency). For both II and DI groups combined, primary
patency was better for open interventions at 1 year (open,
86% vs endovascular, 62%) and at 5 years (open, 54% vsendovascular, 32%). However, this difference did not reach
statistical signiﬁcance (log-rank, P ¼ .081). Comparison of
primary patency between open and endovascular interven-
tion was also performed for II and DI groups separately.
In the II group, patency for open intervention was greater
at 1 year; however, the standard error exceeded 0.10 at
7 months in the endovascular group and at 2.5 years in
the open group (open, 1 year 83% vs endovascular, 1 year
60%; log-rank, P ¼ .335). Similar results were observed
in the DI group, where the SE >0.10 at 6 months in the
endovascular group and 2.5 years in the open group
(open, 1 year 85% vs endovascular, 1 year 56%; log-rank,
P ¼ .139). There were no major amputations in either
group and four minor amputations in the DI group.
DISCUSSION
In 232 patients with IC, 132 were managed nonoper-
atively, whereas 100 ultimately had an intervention per-
formed to treat symptoms of claudication. Neither II nor
DI had a negative impact on overall survival. In addition,
while primary patency was greater for open vs endovascular
interventions, overall primary patency was similar for both
DI and II groups. Patients who had NI or II were older
and were more likely to have diabetes mellitus than patients
who had an interval of medical management prior to inter-
vention (DI). Furthermore, patients in the II group had
JOURNAL OF VASCULAR SURGERY
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indicated by claudication distance and ABI. Likewise,
Charlson comorbidity scores were highest in patients who
had NI and lowest in patients who had DI. The comorbid-
ity scores were predictive of overall survival; NI patients
had the lowest mean survival whereas DI patients had the
longest. Across all intervention groups, hypertension, hy-
perlipidemia, and diabetes were associated with decreased
overall survival, though only diabetes remained signiﬁcant
on multivariate analysis.
Though IC can cause signiﬁcant functional disability,
progression to CLI is relatively rare.1,13 Thus, intervention
for lifestyle limiting claudication is an elective procedure.
Despite this fact, recent data suggest that nearly 17.5% of
patients undergo some type of revascularization within
2 years of referral to a vascular surgeon.11 These interven-
tions may lead to increased morbidity, which in turn could
have a negative impact on patients’ quality of life. In addi-
tion, even if associated morbidity is minimal, there may be
a cumulative effect across multiple interventions with
subsequent reinterventions leading to a detrimental effect
on overall survival. However, our ﬁndings argue against
this theory, as neither II nor DI had a negative effect on
overall survival.
Despite the low risk of limb loss, patients with IC
are at increased risk of cardiovascular morbidity and
mortality.3-6,13,14 Age, hypertension, smoking, diabetes,
and hypercholesterolemia are all established risk factors
for both lower extremity arterial disease and cardiovascular
disease.2,4,5,12,14,16 These risk factors were common in our
study population. Furthermore, diabetes, hyperlipidemia,
and hypertension were associated with increased overall
mortality in our patient cohort. This ﬁnding is consistent
with the large body of literature on this subject. Though
survival differed across the three intervention groups, dia-
betes was the only comorbidity that differed signiﬁcantly
between groups in our study and was the only factor that
maintained signiﬁcance on multivariate analysis. The sel-
ected comorbidities evaluated in the study were otherwise
similar across intervention groups. However, the NI group
did have a signiﬁcantly higher Charlson index compared
with the II or DI groups. The Charlson index is a weighted
scoring system and incorporates a greater number of
comorbidities in addition to those normally regarded as
cardiovascular risk factors. Thus, it seems that this index
was more sensitive in capturing subtle differences in overall
health between the different intervention groups.
Interestingly, neither II nor DI was associated with
worse survival than NI at all. In fact, the lowest mean
survival was observed in those patients who had NI. We
are unaware of similar literature comparing survival in
medically managed patients with IC to those who undergo
open or endovascular intervention. It is difﬁcult to deter-
mine the underlying cause of these observed differences
based on our data. Though individual comorbidities were
generally similar between groups, patients in the NI group
had higher Charlson comorbidity index scores, suggesting
these patients were in a worse state of health comparedwith patients in either the II or DI groups. Nonetheless,
the observation that intervention was not associated with
decreased survival vs NI alone is intriguing and warrants
additional investigation.
Reintervention was common in our series, with a similar
rate of reintervention observed in both the II and DI
groups. We included 232 total patients in our study,
though there were only 38 and 62 patients in the II and
DI groups, respectively. There was a difference observed
in the reintervention rates between these two groups, but
it did not reach statistical signiﬁcance. It is possible that
with a higher powered study, there may actually be a detect-
able difference in reintervention rates between these two
groups. Though reintervention was more common after
endovascular interventions, the type of interventions per-
formed was similar between II and DI groups. Despite
the need for reintervention, patients selected for either II
or DI had longer mean survival than the nonintervention
group. This association is not without bias, as a study
with greater power may have been able to detect subtle
differences in survival between individual intervention
groups.
In addition to the effect of intervention on quality of
life and overall survival, it is also important to consider
the costs of various interventions. Though not addressed
in our study, this question is becoming increasingly impor-
tant in the current climate of cost containment and
accountable-care organizations. The costs of initial inter-
vention, follow-up clinic visits, imaging, and potential rein-
tervention can all be signiﬁcant. In contrast, medical
therapies for claudication (ie, aspirin, statins, smoking
cessation) are quite inexpensive. From an economic stand-
point, the relative value of medical vs surgical intervention
for IC is an important question that requires additional
study.
There are several additional limitations to our study.
First, as a retrospective chart review, patient groups were
nonrandomized. The patients in the NI, II, and DI groups
were potentially subject to signiﬁcant selection bias. We
were certainly aware of this bias; in fact one of our goals
was to better characterize differences between these groups
to differentiate those patients who can be offered an inter-
vention from those who should be managed with medical
therapies alone. Patients who were managed nonoperatively
had a greater number of comorbidities than those who had
an intervention performed, as evidenced by higher scores
in the Charlson comorbidity index. Aside from this index,
we did not perform any risk adjustment to compare the three
intervention groups. As a result, it is difﬁcult to know the
exact impact that intervention had on overall survival. It is
reasonable to suspect that surgeons were more likely to offer
interventions to patients with less medical comorbidity,
making the groups inherently different from one another.
However, it is unlikely that improved survival in the interven-
tion groups was directly related to the performance of an
intervention for claudication. In trying to explain this
observed survival advantage, one might argue that patients
who had an intervention for claudication would then be
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1546 Kret et al December 2013more compliant with medical therapy afterwards. However,
there are no direct data to support this claim. In fact, recent
comparison of medication compliance after coronary artery
bypass grafting vs percutaneous coronary intervention sug-
gested that patients who underwent coronary artery bypass
graft were actually less likely to ﬁll prescriptions than those
who had percutaneous coronary intervention.17 Comparing
medication compliance between intervention vs noninter-
vention groups in vascular surgery may be a valuable ques-
tion for future research.
CONCLUSIONS
Diabetes, hypertension, and hyperlipidemia are recog-
nized cardiovascular disease risk factors and predict overall
mortality in patients with IC referred for vascular surgery
evaluation. Despite a high prevalence of medical comorbid-
ities in these patients, intervention was not associated with
decreased overall survival in appropriately selected patients.
Reintervention is common following both II and DI and
occurs with similar frequency in both groups. Intervention
was not associated with major amputation. II or DI in
patients with IC is not associated with decreased survival
compared with medical management alone nor is it associ-
ated with increased risk of major amputation.
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